Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Why Is Capricor Therapeutics (CAPR) Stock Up +5.44% Today?

Why Is Capricor Therapeutics (CAPR) Stock Up +5.44% Today?

Key Takeaways

  • Shares of CAPR climbed 5.44%, or $0.41, to $7.94 in Friday trading, rebounding from Thursday's close of $7.53.
  • No new company press release, SEC filing or clinical data readout preceded the move; the dominant driver is investor positioning two days before the Nov. 22 FDA target action date for deramiocel.
  • A mechanical rebound is the secondary driver: the stock had fallen in six straight sessions, shedding roughly a third of its value from the Nov. 11 close of $11.22.
  • The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against the cardiomyopathy evidence in July, leaving binary regulatory risk unusually high.
  • Turnover has run above the roughly 4.7 million-share average through the pre-decision stretch, with Thursday's session alone topping 7.9 million shares.
  • News Significance Score: 14/100 - No fresh catalyst, and a move entirely ordinary for this volatile small-cap biotech.
  • Traders are watching the FDA action itself, the breadth of any approved label, and the company's launch readiness and Priority Review Voucher plans.
  • For deeper research, explore the Price Targets, Earnings, and Forecast pages dedicated to the stock.
  • To see which automated strategies are working right now, browse Trending AI Robots.

Opening Summary

Capricor Therapeutics (CAPR) is a San Diego-based clinical-stage biotechnology company with no product revenue, built around deramiocel, an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy, plus an earlier-stage exosome platform. In Friday's session the shares traded at $7.94, up $0.41 or 5.44% from the prior close of $7.53, confirming a move to the upside. The advance came without any new corporate announcement or data release. It is best explained as a rebound from a sharp six-session selloff combined with pre-decision positioning ahead of the FDA's Nov. 22 action date on the deramiocel biologics license application.

A Binary FDA Decision Two Days Away

The single fact dominating the tape is the Nov. 22 target action date on Capricor's BLA for deramiocel. The agency extended the deadline by three months from Aug. 22 after the company submitted a roughly 30,000-page major amendment containing 24-month open-label extension data from the Phase 3 HOPE-3 trial, more than 900 robustness re-analyses, and an integrated summary of efficacy combining HOPE-2 and HOPE-3. Capricor also narrowed its proposed indication to upper-limb impairment in patients aged nine and older, the population in which HOPE-3 met its primary endpoint with a 1.1-point benefit on the PUL 2.0 scale at a p-value of 0.029.

That framing matters because the advisory committee's 9-3 vote in July addressed the cardiomyopathy indication, not the upper-limb endpoint. With the decision landing on a weekend, action could arrive after Friday's close or at the start of next week, and traders have historically added exposure into such deadlines rather than ahead of them. Approval would validate the first therapy specifically targeting upper-limb function in Duchenne; a second complete response letter would leave a company with no revenue and roughly $198.5 million in cash as of Sept. 30 to regroup.

A Rebound From an Oversold Stretch

Today's gain is also the arithmetic mirror of the preceding decline. After surging 26.5% on Nov. 11, when Jones Trading upgraded the stock to Buy with a $25 target, the shares fell in six consecutive sessions from $11.22 to $7.53, a decline of about 33%. That slide came despite Roth Capital lifting its target to $10.50 from $7.00 on Nov. 13 while keeping a Neutral rating, a reminder that published targets on the name span an unusually wide $7 to $54 range. A 5% bounce after a one-third drawdown in a stock with a 0.77 five-year beta and a small float is consistent with routine mean reversion rather than a change in fundamentals.

Market Context and Trading Activity

Participation has been heavy: Thursday's volume of more than 7.9 million shares was well above the roughly 4.7 million-share average, and the Nov. 11 session traded over 6 million. Today's advance is a single-stock story rather than a sector one, and the shares remain more than 80% below their 52-week high of $40.37 and roughly 30% below the Nov. 11 close. Technically, the stock is attempting to reclaim ground lost during the slide, having closed Thursday near the bottom of a wide $7.38-to-$9.12 range. Market capitalization stands at approximately $460 million.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 14 out of 100. No verified news was released before the move; the relevant fundamental backdrop is a scheduled regulatory deadline already public for months, so the news component is weak relative to the company's size. The price component is equally muted: today's 5.44% gain is almost exactly the stock's average absolute daily move of roughly 5.5% over the past 60 sessions, and 22 of those sessions produced moves of similar or greater size. Two ordinary components combine into a low score.

What Comes Next for CAPR

Attention is fixed on the FDA's decision, expected imminently around the Nov. 22 date. Beyond the headline, investors will parse the approved label for how broadly the eligible population is defined, since that determines launch reach. Capricor has said its San Diego facility is operational for initial supply, with capacity expansion targeted for 2027, and that approval could bring a transferable Rare Pediatric Disease Priority Review Voucher, a potential source of non-dilutive capital. The company has also flagged a contractual dispute with NS Pharma over distribution rights, with an arbitration hearing expected in the middle of 2027, and final Phase 1 StealthX vaccine data anticipated in the first half of 2027. With a $42.7 million quarterly net loss and a 10% workforce reduction already in place, funding and execution risk remain live regardless of the decision.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are gathered in one curated section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as conditions change. The Trending AI Robots page is a practical starting point for comparing live strategies before deciding which approaches deserve closer attention.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CAPR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CAPR's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for CAPR moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In 68 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for CAPR turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

CAPR moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.596). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (443.347).

The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Develops innovative products for the treatment of cardiovascular diseases

Industry Biotechnology

Industry
Biotechnology
Address
10865 Road to the Cure
Phone
+1 858 727-1755
Employees
160
Web
https://www.capricor.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.